Structure Therapeutics (NASDAQ:GPCR) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen cut shares of Structure Therapeutics (NASDAQ:GPCR) from a sell rating to a strong sell rating in a research note issued to investors on Sunday.

A number of other equities analysts have also issued reports on the company. HC Wainwright decreased their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Citizens Jmp dropped their price objective on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday. Finally, Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a report on Friday. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Structure Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $53.14 on Friday. The company has a 50 day moving average of $47.63 and a 200-day moving average of $53.95. The firm has a market cap of $3.78 billion, a P/E ratio of -53.14 and a beta of -1.43. Structure Therapeutics has a twelve month low of $15.86 and a twelve month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Equities research analysts forecast that Structure Therapeutics will post -1.64 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in Structure Therapeutics by 18.5% during the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after purchasing an additional 8,444 shares in the last quarter. Invesco Ltd. lifted its position in Structure Therapeutics by 7.6% in the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after buying an additional 30,162 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Structure Therapeutics by 474.9% during the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after buying an additional 145,434 shares during the period. Jump Financial LLC boosted its stake in shares of Structure Therapeutics by 105.9% during the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after buying an additional 32,524 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Structure Therapeutics during the 2nd quarter valued at $3,480,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.